Article
Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation.
Cancer - 15 Jan 2018
Fathi Amir T, Blonquist Traci M, Hernandez Daniela, Amrein Philip C, Ballen Karen K, McMasters Malgorzata, Avigan David E, Joyce Robin, Logan Emma K, Hobbs Gabriela, Brunner Andrew M, Joseph Christelle, Perry Ashley M, Burke Meghan, Behnan Tanya, Foster Julia, Bergeron Meghan K, Moran Jenna A, Ramos Aura Y, Som Tina T, Rae Jessica, Fishman Kaitlyn M, McGregor Kristin L, Connolly Christine, Neuberg Donna S, Levis Mark J
Abstract excerpt
BACKGROUND: Cabozantinib, a tyrosine kinase inhibitor of FMS-like tyrosine kinase 3 (FLT3), MET, AXL, vascular endothelial growth factor receptor, and KIT, is approved for use in multiple malignancies. We assessed the safety and tolerability of cabozantinib in AML, given up-regulation of multiple relevant pathways. METHODS: Adults were eligible if they were 18 years old or older with relapsed/refractory AML or if...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.